Utang agregat perusahaan: Foghorn Therapeutics, Inc. (FHTX)

Foghorn Therapeutics (FHTX) is developing innovative methods to combat blood cancers. The company's price evolution on the GURU.Markets platform is currently at 0.00. The business model relies on the extensive use of external contract research organizations for drug testing, which mitigates dependency on a single supplier. Meanwhile, financial stability remains low, as capital is deployed toward scientific research prior to the product's market entry.

This indicator determines the issuer's creditworthiness through the total volume of external liabilities. The metric aggregates short-term and long-term loans, reflecting the business's actual financial burden. By analyzing borrowed capital, the investor sees the current value of 0.00, which allows for an assessment of debt service rates. The stability of this trend is critically important for Foghorn Therapeutics (FHTX). Sufficient resources ensure the funding of the development of innovative methods to combat resistant forms of cancer.